Key facts
- It has raised $400K; the latest was Angel (individual) ($400K) in Jan 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for SynapseDx
- ·The full record, as it builds
Funding rounds
No funding rounds for SynapseDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SynapseDx
Developer of an AI execution platform intended for regulated enterprise automation. The company's platform offers a comprehensive suite of services, including bioavailability and bioequivalence studies, regulatory compliance support, and pharmacovigilance, all delivered by a team of experienced professionals using state-of-the-art facilities, enabling clients to efficiently navigate the complexities of clinical trials while ensuring high-quality outcomes and adherence to international standards.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 3
- Website
- synapsedx.co.uk/
- Ownership
- Privately Held (backing)
SynapseDx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SynapseDx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SynapseDx in its N-PORT filings yet. We sweep new filings monthly.